Inside TumorSight Risk: What MRI-Based Recurrence Assessment Can and Cannot Tell Clinicians
Dr. Dereck Mush, MD, MBA
CancerIQ
Helps clinicians identify, track, and manage patients with high genetic risk of cancer.
What they do
CancerIQ provides a software platform integrated into electronic health records to help healthcare systems identify patients at high risk for hereditary cancers. Clinicians use the tool to streamline genetic evaluation, risk-stratification, and compliance with personalized cancer prevention plans.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer risk assessment
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Chicago, United States
- Region
- North America
- Founded
- 2013
- Total funding
- $22M raised
Notable investors: Merck Global Health Innovation Fund, Amgen Ventures, McKesson Ventures, OSF Ventures.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Curative Adjuvant Checkpoint Pivot: How Genentech's ATOMIC Approval Redefines Early GI Oncology Economics and Reflex Testing Infrastructure
Dr. Dereck Mush, MD, MBA
Risk-stratified PSA screening is bringing a once-abandoned test back into primary care
Dr. Dereck Mush, MD, MBA
The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA